Akari Therapeutics plc ADR (0.01 USD) financials
$9.72−0.92%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$4.6M | -$15.8M | -$3.2M | -$7.4M | -$3.1M | -$3.5M | -$5.3M | -$2.9M | -$7.4M | -$6.0M | -$5.1M | -$2.5M |
| Net income | -$4.8M | -$14.5M | -$5.3M | -$6.4M | -$1.9M | -$3.7M | -$3.8M | -$2.9M | -$7.6M | -$5.6M | -$4.1M | -$2.9M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-0.01 | $0.00 |
| EBITDA | -$4.6M | -$3.6M | -$3.2M | -$2.2M | -$3.1M | -$3.5M | -$4.3M | -$1.9M | -$5.6M | -$6.0M | -$5.1M | -$2.5M |
| Operating cash flow | -$3.1M | -$2.5M | -$3.0M | -$2.1M | -$3.3M | -$2.1M | -$2.1M | -$1.5M | -$4.9M | -$4.0M | -$4.4M | -$2.4M |
| Free cash flow | -$3.1M | -$2.5M | -$3.0M | -$2.1M | -$3.3M | -$2.1M | -$2.1M | -$1.5M | -$4.9M | -$4.0M | -$4.4M | -$2.4M |
| Diluted shares | 143,317.5M | 118,757.0M | 2,161.4M | 1,633.2M | 62,943.9M | 54,588.3M | 971.9M | 609.7M | 470.9M | 336.3M | 283.8M | 252.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $7.7M | $2.8M | $5.2M | $2.5M | $2.7M | $2.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $693.0K | $732.0K | $754.0K | $861.0K | $879.0K | $928.0K |
| Total assets | $38.6M | $33.9M | $47.9M | $45.4M | $50.9M | $51.0M |
| Total liabilities | $20.0M | $19.5M | $19.6M | $22.7M | $25.3M | $29.2M |
| Shareholders' equity | $18.6M | $14.4M | $28.3M | $22.7M | $25.6M | $21.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology